The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Summit Therapeutics Inc shares valued at $5,894,406 were purchased by Zanganeh Mahkam on Sep 10 ’25. At $17.68 per share, Zanganeh Mahkam acquired 333,394 shares. The insider’s holdings grew to 556,088,090 shares worth approximately $10.34 billion following the completion of this transaction.
Also, Zanganeh Mahkam purchased 5,000 shares, netting a total of over 90,350 in proceeds. Following the buying of shares at $18.07 each, the insider now holds 556,093,090 shares.
Before that, DUGGAN ROBERT W had added 333,394 shares to its account. In a trade valued at $5,894,406, the Co-Chief Executive Officer bought Summit Therapeutics Inc shares for $17.68 each. Upon closing the transaction, the insider’s holdings increased to 333,394 shares, worth approximately $10.34 billion.
As published in their initiating research note from Guggenheim on September 04, 2025, Summit Therapeutics Inc [SMMT] has been a Buy and the price target has been revised to $40. Analysts at Piper Sandler started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid August. As of July 01, 2025, UBS has initiated its “Buy” rating for SMMT. Earlier on June 11, 2025, Leerink Partners initiated its rating. Their recommendation was “an Underperform” for SMMT stock.
Analyzing SMMT Stock Performance
On last trading session, Summit Therapeutics Inc [NASDAQ: SMMT] rose 5.65% to $18.6. The stock’s lowest price that day was $17.7758, but it reached a high of $18.75 in the same session. During the last five days, there has been a drop of approximately -21.85%. Over the course of the year, Summit Therapeutics Inc shares have dropped approximately -2.82%. Shares of the company reached a 52-week high of $36.91 on 04/24/25 and a 52-week low of $15.55 on 04/07/25.
Support And Resistance Levels for Summit Therapeutics Inc (SMMT)
According to the 24-hour chart, there is a support level at 18.00, which, if violated, would cause prices to drop to 17.39. In the upper region, resistance lies at 18.98. The next price resistance is at 19.35. RSI (Relative Strength Index) is 32.42 on the 14-day chart, showing neutral technical sentiment.
Is Summit Therapeutics Inc subject to short interest?
Stocks of Summit Therapeutics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -1.28 million shares to 29.72 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 30.99 million shares. A decline of -4.3% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.7 of the overall float, the days-to-cover ratio (short ratio) decline to 9.7.
Which companies own the most shares of Summit Therapeutics Inc (SMMT)?
In terms of Summit Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 37 in the next 12 months, up nearly 110.23% from the previous closing price of $17.6. Analysts anticipate Summit Therapeutics Inc stock to reach 44 by 2025, with the lowest price target being 21. In spite of this, 1 analysts ranked Summit Therapeutics Inc stock as Buy at the end of 2025. On March 26, 2025, Citigroup assigned a price target of “a Buy” to the stock and upgraded coverage with a $35.
